Educational Cancer Convention Lugano - What is New in Haemato-Oncology?

On behalf of ESO and of the Scientific Committee, I have the pleasure of  inviting you to attend the Educational Cancer Convention Lugano.
The 2010 edition will be devoted to haemato-oncology with a programme developed in co-operation with the International Conference on Malignant Lymphoma and the International Extranodal Lymphoma Study Group.

The synergy between these entities has been devised to provide an overview of the latest developments in the field. In particular, the internationally renowned faculty will offer:
• 3 keynote lectures dealing with relevant biological and clinical aspects of leukaemias and lymphomas
• 4 main sessions addressing malignant lymphomas in general, extranodal lymphomas in particular, myeloma and chronic and acute leukaemias
• Ample time to discuss clinical cases presented both by the faculty and the participants
• Enhanced interactivity during poster discussion sessions

I look forward to welcome you to ECCLU 2010 and to your active participation.

Franco Cavalli
Chair

SCIENTIFIC COMMITTEE
F. Cavalli, Chair, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Costa, ESO Director, Bellinzona and Milan, CH and IT
M.F. Fey, University Hospital, Berne, CH
T.A. Lister, St. Bartholomew's Hospital, London, UK
B. Lowenberg, Erasmus University Medical Centre, Rotterdam, NL
R.A. Stahel, University Hospital, Zurich, CH
P.L. Zinzani, Institute of Hematology "L. e A. Seràgnoli ", University of Bologna, Bologna, IT
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

ORGANISING SECRETARIAT

European School of Oncology
Bellinzona Office
Ospedale Regionale Bellinzona e Valli
CH-6500 Bellinzona, Switzerland
Tel: +41 91 811 8050 - Fax: +41 91 811 8051

ESO Head Office
Via del Bollo 4 - 20123 Milano, Italy
Tel: +39 02 8546 451 - Fax +39 02 8546 4545


Programme and organisation
Chatrina Melcher - ESO Bellinzona  cmelcher@eso.net
Abstracts and programme
Dolores Knupfer - ESO Bellinzona dknupfer@eso.net
Registration
Registration Dept. registration@eso.net


IMPORTANT DEADLINES

29 January 2010     Abstract submission
26 February 2010   Early registration
31 March 2010        Late registration


VENUE
Palazzo dei Congressi, Lugano, Switzerland
Lugano is reachable by plane via Zurich (45-minute flight or 2,5-hour train) or from Milano Malpensa airport (2-hour drive, shuttleservice).

How to reach Lugano:

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
The yearly meeting of IELSG will take place in Lugano before the opening of ECCLU, on Friday 16 April. For registration and further information on the IELSG meeting, please visit www.ielsg.org

TRAVEL GRANTS
A limited number of travel grants are assigned on a competitive basis from among participants from middle-low income countries who have had an abstract accepted for oral or for poster presentation. The curriculum vitae should be submitted at the same time as the abstract (deadline: 29 January) indicating the amount requested to cover economy fare. Successful applicants will be granted registration, accommodation for 2 nights and refund of actual travel costs (flight only) at the end of the Convention.

ACKNOWLEDGMENTS
ESO is grateful to the City of Lugano for their interest and continuous support in the organisation of ECCLU, to ESMO fortheir co-operation and support of travel grants. ESO is furthermore grateful to the International Conference on Malignant Lymphoma and to the International Extranodal Lymphoma Study Group for their commitment and devotion in defining the high-level programme.

ABSTRACT BOOK
The abstract book will be published as a supplement to the European Journal of Cancer and will contain abstracts of the invited lectures and those submitted by the participants that have been accepted for oral or poster presentation.

FACULTY

J.O. Armitage, University of Nebraska Medical Center, Department of Oncology and Hematology, Omaha, US
T. Barbui, Ospedali Riuniti di Bergamo, Division of Haematology, Bergamo, IT
F. Cavalli, Oncology Institute of Southern Switzerland, Medical Director, Bellinzona, CH
A. Costa, European School of Oncology, Scientific Director, Bellinzona, CH and Milan, IT
R. Dalla Favera, Herbert Irving Comprehensive Cancer Center, Columbia University, Department of Pathology and Genetics, New York, US
M. Dreyling, University Hospital Grosshadern, Department of Haemato-Oncology, Munich, DE
A. J.M. Ferreri, San Raffaele Scientific Institute, Department of Oncology, Lymphoid Malignancies Unit, Milan, IT
M.F. Fey, University of Berne, Clinic for Medical Oncology, Berne, CH
M. Ghielmini, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
M. Gospodarowicz, Princess Margaret Hospital - University of Toronto, Department of Radiation Oncology, Toronto, CA
M. Hallek, University Clinic Cologne, Department of Haematology, Cologne, DE
P.W.M. Johnson, Southampton General Hospital, Cancer Research UK Centre, Somers Cancer Research, Southampton, UK
T.A. Lister, St. Bartholomew's Hospital, Department of Medical Oncology, London, UK
B. Lowenberg, Erasmus University Medical Centre, Department of Haematology, Rotterdam, NL
A. Palumbo, University of Turin, Molinette Hospital, Department of Haematology, Turin, IT
M. Ponzoni, San Raffaele Scientific Institute, Pathology Unit, Milan, IT
G. Salles, Centre Hospitalier Lyon Sud, Department of Haematology, Lyon Pierre Benite, FR
R.A. Stahel, University Hospital Zurich, Clinic and Policlinic for Oncology, Zurich, CH
C. Thieblemont, Saint Louis Hospital, Department of Haemato-Oncology, Paris, FR
U. Vitolo, Ospedale Maggiore S. Giovanni Battista, Heamatology Unit, Turin, IT
P.L. Zinzani, University of Bologna, Institute of Hematology and Oncology L. & A. Seragnoli, Bologna, IT
E. Zucca, Oncology Institute of Southern Switzerland, Department of Medical Oncology, Bellinzona, CH

17 April

18 April